TOMI Environmental Solutions Reports Accelerating Growth in SteraMist Service Revenue
Growing SteraMist iHP service revenue is boosting TOMI’s recurring sales and diversifying beyond system shipments.
Rhea-AI Summary
TOMI Environmental Solutions (TOMZ) reported year-to-date 2026 SteraMist iHP Service and Support sales of approximately $1.7 million.
This represents about a 31% increase over full-year 2025 SteraMist iHP Service and Support revenue of roughly $1.3 million and exceeds full-year 2024 revenue, also about $1.3 million. The company highlights that this growth is increasing the recurring-revenue mix from contracted decontamination services and ongoing on-site support. In 2026, TOMI has completed multiple contracted SteraMist deployments, including four engagements each with Integra Pharma and Catalent, plus work for Cleveland Clinic and LFB USA, and four service visits to a Canadian university. TOMI also averages about four on-site support visits per month, including to CDC facilities, and plans to expand contracted service accounts and support through the rest of fiscal 2026.
Positive
- YTD 2026 SteraMist iHP Service and Support sales approximately $1.7 million, about 31% above 2025 full-year $1.3 million
- Service revenue has already surpassed full-year 2024 and 2025 SteraMist iHP Service and Support totals of about $1.3 million each
- Recurring on-site support averages roughly four visits per month across government and commercial facilities, including the CDC
Negative
- None.
Key Figures
- SteraMist service revenue
- $1.7 million
- Year-to-date 2026
- Revenue increase
- 31%
- Year-to-date 2026 versus full-year 2025
- Prior annual service revenue
- $1.3 million
- Each in 2024 and 2025
- Contracted engagements
- 4 times year-to-date
- Each with Integra Pharma and Catalent
- University service frequency
- 4 times year-to-date
- Ongoing Canadian university relationship
- On-site support frequency
- Approximately 4 visits per month
- Recurring support services
Historical Context
-
Reported about $2.3 million in year-to-date SteraMist enclosure purchase orders, exceeding prior comparable orders.
-
Reported Q2 growth across four operating metrics, including support services, with revenue guidance reaffirmed.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Year-to-date SteraMist iHP Service and Support sales of approximately
FREDERICK, Md., Sept. 18, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today reported continued acceleration in its SteraMist iHP Service and Support business. Year-to-date SteraMist iHP Service and Support sales of approximately
This growth in SteraMist iHP Service and Support revenue underscores the increasing recurring-revenue mix of contracted iHP decontamination service and ongoing on-site support engagements. During the year, TOMI has completed multiple contracted SteraMist iHP decontamination service engagements, including deployments with Integra Pharma and Catalent, each four times year-to-date, in addition to contracted engagements with Cleveland Clinic and LFB USA. TOMI also maintains an ongoing SteraMist iHP service relationship with a Canadian university, serviced four times year-to-date. TOMI continues to deliver on-site support services on a recurring basis, averaging approximately four visits per month, at facilities including the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, along with other government and commercial accounts.
“We are seeing sustained demand for deployable SteraMist iHP service and support,” said Reed A. Scott, iHP Service Director and Quality Service Engineer at TOMI Environmental Solutions. “SteraMist allows us to complete a service job quickly, so facilities can return to operations with minimal downtime. Customers consistently point to our turnaround time, reporting, and professionalism, and as we continue to grow and see more opportunities worldwide, we look forward to delivering recurring contracted service that keeps their environments and personnel safely protected.”
The growth in SteraMist iHP Service and Support revenue adds to TOMI's broader revenue diversification strategy, complementing system sales and reinforcing recurring engagement across TOMI's installed base. TOMI remains focused on expanding its contracted service accounts and on-site support for the remainder of fiscal 2026.
About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company providing environmental disinfection and bio-decontamination solutions through manufacturing, sales, and licensing of its Binary Ionization Technology® (BIT®) platform. Developed under a defense grant with DARPA, BIT® utilizes low-percentage hydrogen peroxide to produce ionized hydrogen peroxide (iHP®) fog. SteraMist® products serve hospitals, laboratories, government and military installations, cruise ships, office buildings, schools, restaurants, food processing facilities, and residences, delivering protection against a broad range of bacteria, viruses, mold, mycotoxins, and biological and chemical warfare agents. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the life science sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Zach Nevas
IMS Investor Relations
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which customers have used TOMI’s SteraMist iHP decontamination services in 2026?
In 2026, TOMI has completed multiple contracted SteraMist iHP decontamination engagements with Integra Pharma and Catalent, each serviced four times year-to-date. Additional contracted engagements include Cleveland Clinic and LFB USA. TOMI also maintains an ongoing SteraMist iHP service relationship with a Canadian university, serviced four times year-to-date, and provides recurring on-site support at facilities including the Centers for Disease Control and Prevention (CDC) in Atlanta, along with other government and commercial accounts.
How does the SteraMist iHP Service and Support business fit TOMI’s broader strategy?
The company states that growth in SteraMist iHP Service and Support revenue contributes to revenue diversification by complementing SteraMist system sales and reinforcing recurring engagement across TOMI’s installed base. TOMI reports that it remains focused on expanding its contracted service accounts and on-site support for the remainder of fiscal 2026.